Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17194995 | 0.85 | LRRK2 (0.40) | CYP2C19CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL18415118 | 0.82 | ALDH1A1 (0.40) | CYP2C19CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL13564332 | 0.77 | CASP6 (0.48) | CYP2C19CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL15829876 | 0.77 | CYP1A2 (0.49) | CYP2C19CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL16891571 | 0.72 | CYP2C19 (0.46) | CYP2C19CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL26855947 | 0.72 | CYP2E1 (0.42) | CYP2C19CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL22635577 | 0.72 | CYP2C9 (0.43) | CYP2C19CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL9261080 | 0.71 | KMT2A (0.50) | CASP6TRPA1ALDH1A1TDP1TSHR | |
| SCHEMBL20102297 | 0.71 | CYP2E1 (0.45) | CYP2C19CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL9258894 | 0.71 | KDM4E (0.50) | CYP1A2LMNAPKMALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9765068-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160368907-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150344434-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150191432-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191432-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | CYP2C19 3456/4885CYP2E1 2425/4885CYP2A6 4000/4885 |
| US-20150344433-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | CYP2C19 3407/4885CYP2E1 2456/4885CYP2A6 3906/4885 |
| US-20160368907-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | CYP2C19 3456/4885CYP2E1 2425/4885CYP2A6 4000/4885 |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | CYP2C19 3509/4885CYP2E1 2548/4885CYP2A6 3873/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | CYP2C19 2802/4885CYP2E1 1748/4885CYP2A6 3503/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | CYP2C19 2067/4885CYP2E1 2097/4885CYP2A6 3245/4885 |
| US-20180162847-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | PRMT5, PRMT1, PRMT3 | CYP2C19 3407/4885CYP2E1 2456/4885CYP2A6 3906/4885 |
| US-20150344434-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | CYP2C19 3097/4885CYP2E1 2010/4885CYP2A6 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.